“Title: SRP-4045: A 39-week intravenous infusion toxicity study in male cynomolgus monkeys with an 8-week recovery period”
✓ VerifiedFDA pharmacology/toxicology review, p. 40Source ↗
Pivotal GLP studies
12-wk IV, 22-wk IV (terminated) and 26-wk SC mouse; 12-wk and 39-wk IV monkey; 10-wk IV juvenile rat
“general toxicology (12-, 22-, and 26-week IV in mouse; 12- and 39-week IV in monkey) studies”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Route in tox
IV bolus/30-min infusion; SC for 26-week mouse because chronic IV infeasible (injection-site toxicity)
“Although the clinical route of administration is IV, the adverse effects at the injection site in the 22-week mouse IV study, indicated that the IV route for the 26-week duration is not feasible.”
✓ VerifiedFDA pharmacology/toxicology review, p. 73Source ↗